Skip to main content
4SC AG logo

4SC AG — Investor Relations & Filings

Ticker · VSC ISIN · DE000A3E5C40 LEI · 391200QOKN7LGVP0RQ86 F Manufacturing
Open in API
Filings indexed 719 across all filing types
Latest filing 2018-08-09 Earnings Release
Country DE Germany
Listing F VSC

About 4SC AG

https://www.4sc.com/

4SC AG is a biopharmaceutical company that formerly focused on the research and development of small-molecule drugs for cancer treatment. The company's strategy centered on addressing diseases with high unmet medical needs by developing innovative therapies that targeted epigenetic mechanisms of action. According to the company's official statements, it currently has no products under development and no operational business.

Recent filings

Filing Released Lang Actions
4SC provides Q2 and H1 2018 update
Earnings Release Classification · 1% confidence The document is titled "4SC provides Q2 and H1 2018 update" and explicitly states that the company "today published its Half-Year Report and provided a business update for the six months ended 30 June 2018". This content describes a comprehensive financial report for a period shorter than a year (H1 2018). This aligns perfectly with the definition of an Interim / Quarterly Report (Code: IR). Although it mentions the publication of the report and a conference call, the core content provided is the summary and highlights of the financial period, making it more than just a simple announcement of publication (RPA/RNS). The mention of 'Half Year Report' is the key differentiator pointing to IR over ER (which is typically quarterly). H1 2018
2018-08-09 English
4SC AG: Conference call to be hosted on 9 August 2018 to present the half-year report 2018
Report Publication Announcement Classification · 1% confidence The document explicitly states: '4SC AG: Conference call to be hosted on 9 August 2018 to present the half-year report 2018' and '4SC AG (4SC, FSE Prime Standard: VSC) will publish its half-year report 2018 on 9 August 2018.' This indicates the document is an announcement about the upcoming release of a periodic financial report (the half-year report) and the associated conference call details. A half-year report corresponds to an Interim/Quarterly Report (IR). However, the document itself is not the comprehensive report; it is an announcement providing the date of publication and details for an investor call. According to Rule 2 (The 'MENU VS MEAL' Rule), if a document announces the publication of a report and provides details for an associated event (like a conference call), it is best classified as a Report Publication Announcement (RPA), as it is announcing the release rather than containing the full financial statements itself. The document length (5162 chars) is consistent with a short announcement.
2018-08-02 English
First patient enrolled in 2nd dose cohort of Phase Ib/II study SENSITIZE of domatinostat (4SC-202) + pembrolizumab in melanoma
Regulatory Filings Classification · 1% confidence The document is a press release dated July 31, 2018, announcing a clinical trial update: 'First patient enrolled in 2nd dose cohort of Phase Ib/II study SENSITIZE of domatinostat (4SC-202) + pembrolizumab in melanoma'. It contains key highlights, future data expectations (H2 2018, H1 2019), and background information on the drug and study. This format, which announces specific operational or clinical progress rather than comprehensive financial results (like 10-K or IR) or formal voting results, aligns best with a general regulatory announcement or news release. Since it is a specific operational update that doesn't fit the other specialized categories (like DIV, CAP, ER, etc.), the most appropriate classification is the general regulatory announcement/news category, RNS, as per the definition: 'General regulatory announcements and fallback category for miscellaneous filings that do not neatly fit into other specific categories.' It is not an Earnings Release (ER) as it focuses on clinical progress, not financial performance highlights.
2018-07-31 English
4SC AG: Stifel Nicolaus Europe initiates research coverage on 4SC with a buy rating
Regulatory Filings Classification · 1% confidence The document is a press release dated July 18, 2018, announcing that Stifel Nicolaus Europe has initiated research coverage on 4SC AG with a 'buy' rating. It explicitly states that the full research report is available upon request from the analyst or downloadable from the company website. This document is not the research report itself, nor is it a standard regulatory filing like a 10-K or ER. It is an announcement about the availability of external research coverage. This fits best under the general category for regulatory announcements or news releases that don't fit a more specific financial report type. Since it is a news item about external research coverage, and not a formal financial report, the most appropriate classification is Regulatory Filings (RNS) as a general news dissemination, although it is closely related to investor relations material. Given the options, RNS serves as the best general news/announcement category for non-standard regulatory disclosures.
2018-07-18 English
4SC AG: Positive safety review of 4SC's Phase Ib/II SENSITIZE study of domatinostat (4SC-202) + pembrolizumab in melanoma
Regulatory Filings Classification · 1% confidence The document is a press release dated July 3, 2018, announcing positive safety review results for a clinical study (SENSITIZE) involving the drug domatinostat. It discusses clinical trial progress, safety data evaluation by a Safety Review Committee (SRC), and future data release timelines (H2 2018, H1 2019). This type of announcement, detailing clinical trial updates and safety findings, is characteristic of general corporate news releases related to drug development. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a formal report (AR, IR). Since it is a specific announcement about clinical progress and safety, and not a general regulatory filing (RNS) or a presentation (IP), the most appropriate category for this type of specific corporate operational update, especially in the biotech/pharma sector, is often classified under general Regulatory Filings (RNS) if a more specific category like 'Clinical Trial Update' is unavailable. However, given the options, this is a specific corporate news item. It is not an Earnings Release (ER), nor a formal Financial Report (IR/10-K). It is a news announcement about R&D progress. In the absence of a dedicated 'Clinical Trial Update' category, RNS (Regulatory Filings/General Announcements) serves as the best fit for non-standard, time-sensitive corporate news that is disseminated via official channels (DGAP in this case).
2018-07-03 English
4SC AG: New data supports resminostat's mechanism of action in CTCL maintenance therapy
Regulatory Filings Classification · 1% confidence The document is a press release dated June 28, 2018, announcing new scientific data regarding the drug resminostat and upcoming poster presentations at a cancer research congress (EACR). It discusses clinical development plans (RESMAIN study) and provides background information on the drug and the disease (CTCL). This content is characteristic of a general corporate or scientific update, not a formal regulatory filing like a 10-K, an earnings release (ER), or a specific financial report (IR, AR). Since it is a news announcement detailing scientific progress and upcoming conference participation, it fits best under the general 'Regulatory Filings' (RNS) category, which serves as a broad category for corporate news that doesn't fit more specific financial or governance codes. It is not a short announcement about publishing a report, so RPA is less appropriate than RNS for substantive scientific news.
2018-06-28 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.